Trial Gives New Guidance for Choosing Initial PsA Treatment

Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.
Medscape Medical News